MIT researchers create DIY jab for extended birth control
Scientists at the Massachusetts Institute of Technology (MIT) have developed a new self-injecting contraceptive that could offer long-term pregnancy prevention without requiring surgical procedures or frequent doctor visits. The injection, containing microscopic crystals that assemble under the skin, gradually releases hormones that prevent ovulation.
Currently, contraceptive implants last for years but require insertion by a trained professional, while contraceptive shots typically last only three months. The new self-administered injection aims to bridge this gap by providing extended protection without medical intervention. Although human trials have not yet been conducted, researchers are optimistic about its effectiveness.
Promising results in animal testing
In trials on rats, the injectable formulation sustained drug release for at least 97 days, potentially even longer depending on modifications.
“SLIM [self-aggregating long-acting injectable microcrystals] could significantly reduce the frequency of contraceptive administration compared to current self-administered methods,” the study, published in Nature Chemical Engineering, stated.
Enhanced comfort and accessibility
Dr. Giovanni Traverso, a co-author of the study, emphasized the challenge of designing a solution that patients could comfortably self-administer.
“Our goal was to create a method that minimizes discomfort by using smaller needles, reducing bruising and bleeding,” he explained.
He added that the innovation could be especially beneficial for individuals in low-resource settings, where access to contraceptive services is limited.
“We anticipate that SLIM could expand family planning options, particularly for those with restricted access to healthcare facilities,” Dr. Traverso said.
Potential applications beyond contraception
Beyond birth control, researchers believe this injectable system could be adapted for other long-term drug delivery applications, including treatments for HIV, tuberculosis, schizophrenia, chronic pain, and metabolic disorders.
“This is a simple system involving a solvent, the drug, and a small amount of bioresorbable polymer. We are now exploring the best applications, whether for contraception or other medical needs,” Dr. Traverso noted.
Moving forward, scientists plan to conduct preclinical studies to assess how the injectable formulation behaves in human skin, paving the way for potential clinical trials.
